181 related articles for article (PubMed ID: 32403181)
1. Linezolid is safe on platelet count for AML patients during myelosuppression after consolidation chemotherapy.
Zhou D; Shi T; Zhao S; Zhu J; Zhu L; Yang X; Xie W; Ye X
J Clin Pharm Ther; 2020 Aug; 45(4):755-758. PubMed ID: 32403181
[TBL] [Abstract][Full Text] [Related]
2. Effect of Linezolid on Hematologic Recovery in Newly Diagnosed Acute Myeloid Leukemia Patients Following Induction Chemotherapy.
Nedved AN; DeFrates SR; Hladnik LM; Stockerl-Goldstein KE
Pharmacotherapy; 2016 Oct; 36(10):1087-1094. PubMed ID: 27521990
[TBL] [Abstract][Full Text] [Related]
3. Linezolid-induced thrombocytopenia in patients with acute myeloid leukemia: a matched case-control study.
Chen C; Li Y; Yu J; Qian S
Clin Transl Oncol; 2022 Mar; 24(3):540-545. PubMed ID: 34716540
[TBL] [Abstract][Full Text] [Related]
4. Acute myeloid leukemia in Manitoba. The consequences of standard "7 + 3" remission-induction therapy followed by high dose cytarabine postremission consolidation for myelosuppression, infectious morbidity, and outcome.
Bow EJ; Kilpatrick MG; Scott BA; Clinch JJ; Cheang MS
Cancer; 1994 Jul; 74(1):52-60. PubMed ID: 8004583
[TBL] [Abstract][Full Text] [Related]
5. Idarubicin Dose Escalation During Consolidation Therapy for Adult Acute Myeloid Leukemia.
Bradstock KF; Link E; Di Iulio J; Szer J; Marlton P; Wei AH; Enno A; Schwarer A; Lewis ID; D'Rozario J; Coyle L; Cull G; Campbell P; Leahy MF; Hahn U; Cannell P; Tiley C; Lowenthal RM; Moore J; Cartwright K; Cunningham I; Taper J; Grigg A; Roberts AW; Benson W; Hertzberg M; Deveridge S; Rowlings P; Mills AK; Gill D; Bardy P; Campbell L; Seymour JF;
J Clin Oncol; 2017 May; 35(15):1678-1685. PubMed ID: 28368672
[TBL] [Abstract][Full Text] [Related]
6. Risk factors for linezolid-associated thrombocytopenia and negative effect of carbapenem combination.
Kaya Kılıç E; Bulut C; Sönmezer MÇ; Ozel Ö; Ataman Hatipoğlu Ç; Tuncer Ertem G; Tülek N; Kınıklı S
J Infect Dev Ctries; 2019 Oct; 13(10):886-891. PubMed ID: 32084018
[TBL] [Abstract][Full Text] [Related]
7. Pilot study of Mylotarg, idarubicin and cytarabine combination regimen in patients with primary resistant or relapsed acute myeloid leukemia.
Alvarado Y; Tsimberidou A; Kantarjian H; Cortes J; Garcia-Manero G; Faderl S; Thomas D; Estey E; Giles FJ
Cancer Chemother Pharmacol; 2003 Jan; 51(1):87-90. PubMed ID: 12497211
[TBL] [Abstract][Full Text] [Related]
8. Prophylactic platelet transfusion threshold during therapy for adult acute myeloid leukemia: 10,000/microL versus 20,000/microL.
Navarro JT; Hernández JA; Ribera JM; Sancho JM; Oriol A; Pujol M; Millá F; Feliu E
Haematologica; 1998 Nov; 83(11):998-1000. PubMed ID: 9864920
[TBL] [Abstract][Full Text] [Related]
9. Association of clinical factors with thrombocytopenia in patients receiving linezolid treatment: a retrospective study.
Thi Phuong Thao L; Duc Trung N; Thi My L; Minh Hong L; Viet Hoan B; Quang Hung V; Dang Hai P
J Infect Dev Ctries; 2024 Feb; 18(2):285-290. PubMed ID: 38484357
[TBL] [Abstract][Full Text] [Related]
10. Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia.
Wiernik PH; Banks PL; Case DC; Arlin ZA; Periman PO; Todd MB; Ritch PS; Enck RE; Weitberg AB
Blood; 1992 Jan; 79(2):313-9. PubMed ID: 1730080
[TBL] [Abstract][Full Text] [Related]
11. [Efficacy and safety of IA regimen containing different doses of idarubicin in de-novo acute myeloid leukemia for adult patients].
Sun AN; Tian XP; Cao XS; Ouyang J; Gu J; Xu KL; Yu K; Zeng QS; Sun ZM; Chen GA; Gao SJ; Zhou J; Wang JH; Yang LH; Luo JM; Zhang M; Guo XH; Wang XM; Zhang X; Shi KQ; Sun H; Ding XM; Hu JD; Zheng RJ; Zhao HG; Hou M; Wang X; Chen FP; Zhu Y; Liu H; Huang DP; Liao AJ; Ma LM; Su LP; Liu L; Zhou ZP; Huang XB; Sun XM; Wu DP
Zhonghua Xue Ye Xue Za Zhi; 2017 Dec; 38(12):1017-1023. PubMed ID: 29365393
[No Abstract] [Full Text] [Related]
12. Risk factors for linezolid-induced thrombocytopenia in patients without haemato-oncologic diseases.
Choi GW; Lee JY; Chang MJ; Kim YK; Cho Y; Yu YM; Lee E
Basic Clin Pharmacol Toxicol; 2019 Feb; 124(2):228-234. PubMed ID: 30171804
[TBL] [Abstract][Full Text] [Related]
13. Idarubicin, cytarabine, and topotecan in patients with refractory or relapsed acute myelogenous leukemia and high-risk myelodysplastic syndrome.
Lee ST; Jang JH; Suh HC; Hahn JS; Ko YW; Min YH
Am J Hematol; 2001 Dec; 68(4):237-45. PubMed ID: 11754412
[TBL] [Abstract][Full Text] [Related]
14. Health economic impact of high-dose versus standard-dose cytarabine induction chemotherapy for acute myeloid leukaemia.
Fedele PL; Avery S; Patil S; Spencer A; Haas M; Wei A
Intern Med J; 2014 Aug; 44(8):757-63. PubMed ID: 24863325
[TBL] [Abstract][Full Text] [Related]
15. A randomized phase 2 study of idarubicin and cytarabine with clofarabine or fludarabine in patients with newly diagnosed acute myeloid leukemia.
Jabbour E; Short NJ; Ravandi F; Huang X; Xiao L; Garcia-Manero G; Plunkett W; Gandhi V; Sasaki K; Pemmaraju N; Daver NG; Borthakur G; Jain N; Konopleva M; Estrov Z; Kadia TM; Wierda WG; DiNardo CD; Brandt M; O'Brien SM; Cortes JE; Kantarjian H
Cancer; 2017 Nov; 123(22):4430-4439. PubMed ID: 28708931
[TBL] [Abstract][Full Text] [Related]
16. A novel PrECOG (PrE0901) dose-escalation trial using eltrombopag: enhanced platelet recovery during consolidation therapy in acute myeloid leukemia.
Strickland SA; Wang XV; Cerny J; Rowe JM; Rybka W; Tallman MS; Litzow M; Lazarus HM
Leuk Lymphoma; 2020 Sep; 61(9):2191-2199. PubMed ID: 32476546
[TBL] [Abstract][Full Text] [Related]
17. The association between risk factors and time of onset for thrombocytopenia in Japanese patients receiving linezolid therapy: a retrospective analysis.
Ichie T; Suzuki D; Yasui K; Takahashi H; Matsuda M; Hayashi H; Sugiura Y; Sugiyama T
J Clin Pharm Ther; 2015 Jun; 40(3):279-84. PubMed ID: 25732525
[TBL] [Abstract][Full Text] [Related]
18. Retrospective cohort chart review study of factors associated with the development of thrombocytopenia in adult Japanese patients who received intravenous linezolid therapy.
Niwa T; Suzuki A; Sakakibara S; Kasahara S; Yasuda M; Fukao A; Matsuura K; Goto C; Murakami N; Itoh Y
Clin Ther; 2009 Oct; 31(10):2126-33. PubMed ID: 19922883
[TBL] [Abstract][Full Text] [Related]
19. A retrospective study of the risk factors for linezolid-induced thrombocytopenia and anemia.
Hanai Y; Matsuo K; Ogawa M; Higashi A; Kimura I; Hirayama S; Kosugi T; Nishizawa K; Yoshio T
J Infect Chemother; 2016 Aug; 22(8):536-42. PubMed ID: 27321773
[TBL] [Abstract][Full Text] [Related]
20. [IDA-FLAG (idarubicin, fludarabine, high dosage cytarabine and G-CSF)--an effective therapy regimen in treatment of recurrent acute myelocytic leukemia in children and adolescents. Initial results of a pilot study].
Fleischhack G; Graf N; Hasan C; Ackermann M; Breu H; Zernikow B; Bode U
Klin Padiatr; 1996; 208(4):229-35. PubMed ID: 8926688
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
